1. Ainsworth S., Milligan D., 2002. Surfactant therapy for respiratory distress syndrome in premature neonates. Respiration Journal, 1(6): 417- 433.
2. Avery M., Mead J., 1959. Surface properties in relation to atelectasis and hyaline membrane disease. American Journal of Diseases of Children, 97: 517- 523.
3. Atalay C., Dogan N., Aykan S., Gundogdu C., Keles M.S., 2010. The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. Singapore Medical Journal, 51(6): 501.
4. El-Hage N., Gurwell J., Singh I., Knapp P., Nath A., Hauser K., 2005. Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia, 50: 91–106.
5. Eugenin E., Aversa T., Lopez L., Calderon T., Berman J., 2003. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis.
Journal of Neurochemistry, 85: 1299-1311.
7. Gunther A., Schmidt R., Harodt J., Schmehl T., Walmrath D., Ruppert C., Grimminger F., Seeger W., 2002. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. European Respiratory Journal, 19: 797-804.
8. Jeffrey A. W.H., Timothy E.W., 2002. Hydrophobic Surfactant Proteins lung function and Disease. New England Journal of Medicine, 347(26): 2141 -2148.
9. Karol M., 1994. Animal models of occupational asthma. European Respiratory Journal, 3(7): 555-568.
10. Keith C., Anuja S., Raymond B., Mark W., Fernando R., June L., Jerry J., 2000. Function and Composition of Pulmonary Surfactant and Surfactant-Derived Fatty Acid Profiles Are Altered in Young Adults With Cystic Fibrosis. Laboratory and Animal Investigations, 118(1): 174-184.
11. Lin C., Chen C., Chen J., Lee H., 2006. Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. Journal of Cell Biochemistry, 99: 1216-1232.
12. Morton N., 1990. Exogenous surfactant treatment for the adult respiratory distress syndrome. A Historical Perspective, 45: 825-830.
13. Griese M., 1999. Pulmonary surfactant in health and human lung diseases: state of the art. European Respiration Journal, 13: 1455-1476.
14. Meloni F., Alberti A.,Bulgheron A., Lupi A., Paschetto E., Marone B.,Rodi G., Fietta A., Luisetti M., Baritussio A., 2002. Surfactant apoprotein A modulates IL-8 and monocyte chemotactin peptid-1 production. European Respiration Journal, 19: 1128-1135.
15. Park I., Wang J., Groopman J., 2001. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood, 97: 352-358.
16. Quinones M.P., Estrada C.A., Jimenez F., Martinez H., Willmon O., Kuziel W.A., 2007. CCL2-independent role of CCR2 in immune responses against Leishmania major. Parasite Immunology, 29(4): 211-217.
17. Robin B., Cheryl A.C., 2006. Surfactant. Newborn and Infant Nursing Review, 6(2): 87-93.
18. Rossi G., 1986. Bronchoalveolar lavage in the investigation of disorders in the lower respiratory tract. European Journal of Respiratory Diseases, 69: 293-315.
19. Ritter U., Korner H., 2002. Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunology, 24(6): 295-301.
20. Shin Y.S., Takeda K.W., Gelfand E.W., 2009. Understanding asthma using animal models. Allergy, Asthma and Immunology Research, 1(1): 10-18.
21. Taeusch H.W., 2000. Treatment of acute (adult) respiratory distress syndrome. The Holy Grail of Surfactant Therapy. Biology of the Neonate, 77(1): 2-8.
22. Takaishi H., Taniguchi T., Takahashi A., Ishikawa Y., Yokoyama M., 2003. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochemistry and Biophysics Research Community, 305: 122-128.
23. Traynor T., Kuziel W., Toews G., Huffnagle G., 2000. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. Journal Immunology, 164(4): 2021-2027.
24. Veit J.E., Norbert K., Jens M. H., 2009. Therapeutic use of surfactant components in allergic asthma. Naunyn-Schmiedeberg’s Arch Pharmacology, 379: 217-224.
25. Wright J.R., 2003. Pulmonary surfactant: a front line of lung host defense. Journal of Clinical Investigation, 111: 1453-1455.
26. Wright J., Cosio M., Churg A., 2008. Animal models of chronic obstructive pulmonary disease. Americam Journal of Physiology, 295: L1-L15.